Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
for Juvenile Psoriatic Arthritis
Drug: Secukinumab
Sites in Salt Lake City +10 more locations
Sponsor: Novartis Pharmaceuticals
Sex: All·Age: 2 - 17
Code: NCT06751238·Phase 1·Recruiting·Listed Dec 2024